NCT06916091

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

A Phase 1, Investigator- and Participant-Blinded, Placebo Controlled, Randomized, Single Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it. The study will last approximately 10 weeks excluding a screening period.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	Eloralintide	Administered subcutaneously (SC)
DRUG	Placebo	Administered SC

Timeline

• Start date: 2025-04-21
• Primary completion: 2025-09-09
• Completion: 2025-09-09
• First posted: 2025-04-08
• Last updated: 2025-11-19

Locations

1 site across 1 country: Singapore

Regulatory

• FDA-regulated drug study